Search Results - "Egorin, Merrill"

Combined PDGFR and HDAC Inhibition Overcomes PTEN Disruption in Chordoma by Lee, Dae-Hee, Zhang, Ying, Kassam, Amin B, Park, Myung-Jin, Gardner, Paul, Prevedello, Daniel, Henry, Stephanie, Horbinski, Craig, Beumer, Jan H, Tawbi, Hussein, Williams, Brian J, Shaffrey, Mark E, Egorin, Merrill J, Abounader, Roger, Park, Deric M

“…The majority of chordomas show activation of the platelet-derived growth factor receptor (PDGFR). Based on in vitro intertumoral variation in response to…”
Get full text

Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma by Badros, Ashraf, Burger, Angelika M, Philip, Sunita, Niesvizky, Ruben, Kolla, Sarah S, Goloubeva, Olga, Harris, Carolynn, Zwiebel, James, Wright, John J, Espinoza-Delgado, Igor, Baer, Maria R, Holleran, Julianne L, Egorin, Merrill J, Grant, Steven

“…Purpose: Vorinostat, a histone deacetylase inhibitor, enhances cell death by the proteasome inhibitor bortezomib in vitro . We sought to test the combination…”
Get full text

A Phase I Trial of the ABCB1 Inhibitor, Oral Valspodar, in Combination With Paclitaxel in Patients With Advanced Solid Tumors by Fracasso, Paula M., Fisher, George A., Goodner, Sherry A., Beumer, Jan H., Egorin, Merrill J., Fears, Carole L., Wildi, Jonathan D., Jones, Gary J., Pearce, Tillman E., Sikic, Branimir I.

“…Multidrug resistance mediated by P-glycoprotein is a potential obstacle to cancer treatment. This phase 1 trial determined the safety of paclitaxel with…”
Get full text

Cisplatin Preferentially Binds Mitochondrial DNA and Voltage-Dependent Anion Channel Protein in the Mitochondrial Membrane of Head and Neck Squamous Cell Carcinoma: Possible Role in Apoptosis by Yang, Zejia, Schumaker, Lisa M, Egorin, Merrill J, Zuhowski, Eleanor G, Guo, Zhongmin, Cullen, Kevin J

“…Purpose: Cisplatin adducts to nuclear DNA (nDNA) are felt to be the molecular lesions that trigger apoptosis, but the mechanism linking nDNA adduct formation…”
Get full text

In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc/Max dimerization by Clausen, Dana M, Guo, Jianxia, Parise, Robert A, Beumer, Jan H, Egorin, Merrill J, Lazo, John S, Prochownik, Edward V, Eiseman, Julie L

“…The c-Myc oncoprotein is overexpressed in many tumors and is essential for maintaining the proliferation of transformed cells. To function as a transcription…”
Get more information

Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08 by Wen, Patrick Y, Yung, W K Alfred, Lamborn, Kathleen R, Dahia, Patricia L, Wang, Yanfeng, Peng, Bin, Abrey, Lauren E, Raizer, Jeffrey, Cloughesy, Timothy F, Fink, Karen, Gilbert, Mark, Chang, Susan, Junck, Larry, Schiff, David, Lieberman, Frank, Fine, Howard A, Mehta, Minesh, Robins, H Ian, DeAngelis, Lisa M, Groves, Morris D, Puduvalli, Vinay K, Levin, Victor, Conrad, Charles, Maher, Elizabeth A, Aldape, Kenneth, Hayes, Michael, Letvak, Laurie, Egorin, Merrill J, Capdeville, Renaud, Kaplan, Richard, Murgo, Anthony J, Stiles, Charles, Prados, Michael D

“…Purpose: Phase I: To determine the maximum tolerated doses, toxicities, and pharmacokinetics of imatinib mesylate (Gleevec) in patients with malignant gliomas…”
Get full text

Phase I Study of Vorinostat in Patients With Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study by RAMALINGAM, Suresh S, KUMMAR, Shivaani, IVY, S. Percy, BELANI, Chandra P, EGORIN, Merrill J, SARANTOPOULOS, John, SHIBATA, Stephen, LORUSSO, Patricia, YERK, Mara, HOLLERAN, Julianne, YAN LIN, BEUMER, Jan H, HARVEY, R. Donald

“…Vorinostat is the first US Food and Drug Administration-approved histone deacetylase inhibitor and is indicated for the treatment of refractory cutaneous…”
Get full text

Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced Cancer by SOLIT, David B, IVY, S. Percy, LARSON, Steven, SCHWARTZ, Lawrence, EGORIN, Merrill J, ROSEN, Neal, SCHER, Howard I, KOPIL, Catherine, SIKORSKI, Rachel, MORRIS, Michael J, SLOVIN, Susan F, KELLY, W. Kevin, DELACRUZ, Anthony, CURLEY, Tracy, HELLER, Glenn

“…Purpose: To define the maximum tolerated dose (MTD), toxicities, and pharmacokinetics of 17-allylamino-17-demethoxygeldanamycin (17-AAG) when administered…”
Get full text

Phase I and Pharmacokinetic Study of Vorinostat, A Histone Deacetylase Inhibitor, in Combination with Carboplatin and Paclitaxel for Advanced Solid Malignancies by RAMALINGAM, Suresh S, PARISE, Robert A, BELANI, Chandra P, RAMANANTHAN, Ramesh K, LAGATTUTA, Theodore F, MUSGUIRE, Lori A, STOLLER, Ronald G, POTTER, Douglas M, ARGIRIS, Athanassios E, ZWIEBEL, James A, EGORIN, Merrill J

“…Purpose: The primary objective of this study was to determine the recommended phase II doses of the novel histone deacetylase inhibitor vorinostat when…”
Get full text

Phase II Study of Imatinib Mesylate Plus Hydroxyurea in Adults With Recurrent Glioblastoma Multiforme by REARDON, David A, EGORIN, Merrill J, DOWELL, Jeannette M, BADRUDDOJA, Michael A, MCLENDON, Roger E, LAGATTUTA, Theodore F, KICIELINSKI, Kimberly P, DRESEMANN, Gregor, SAMPSON, John H, FRIEDMAN, Allan H, SALVADO, August J, FRIEDMAN, Henry S, QUINN, Jennifer A, RICH, Jeremy N, GURURANGAN, Idharan, VREDENBURGH, James J, DESJARDINS, Annick, SATHORNSUMETEE, Sith, PROVENZALE, James M, HERNDON, James E

“…We performed a phase II study to evaluate the combination of imatinib mesylate, an adenosine triphosphate mimetic, tyrosine kinase inhibitor, plus hydroxyurea,…”
Get full text

Phase I Pharmacokinetic and Pharmacodynamic Study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an Inhibitor of Heat-Shock Protein 90, in Patients With Advanced Solid Tumors by RAMANATHAN, Ramesh K, EGORIN, Merrill J, ERLICHMAN, Charles, REMICK, Scot C, RAMALINGAM, Suresh S, NARET, Cynthia, HOLLERAN, Julianne L, TENEYCK, Cynthia J, PERCY IVY, S, BELANI, Chandra P

“…To define the maximum tolerated dose, toxicities, pharmacokinetics, and pharmacodynamics of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17DMAG)…”
Get full text

Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice by Guo, Jianxia, Parise, Robert A, Joseph, Erin, Egorin, Merrill J, Lazo, John S, Prochownik, Edward V, Eiseman, Julie L

“…Objectives c-Myc is commonly activated in many human tumors and is functionally important in cellular proliferation, differentiation, apoptosis and cell cycle…”
Get full text

Phase I Study of Decitabine in Combination with Vorinostat in Patients with Advanced Solid Tumors and Non-Hodgkin's Lymphomas by STATHIS, Anastasios, HOTTE, Sebastien J, WANG, Lisa, ZHANG, Wen-Jiang, ESPINOZA-DELGADO, Igor, HOLLERAN, Julianne L, EGORIN, Merrill J, SIU, Lillian L, CHEN, Eric X, HIRTE, Holger W, OZA, Amit M, MORETTO, Patricia, WEBSTER, Sheila, LAUGHLIN, Anne, STAYNER, Lee-Anne, MCGILL, Shauna

“…This phase I study evaluated the safety, tolerability, pharmacokinetics, and preliminary efficacy of the combination of decitabine with vorinostat. Patients…”
Get full text

Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG) by Jaeckle, Kurt A., Anderson, S. K., Twohy, Erin L., Dixon, Jesse G., Giannini, Caterina, Jenkins, Robert, Egorin, Merrill J., Sarkaria, Jann N., Brown, Paul D., Flynn, P. J., Schwerkoske, John, Buckner, Jan C., Galanis, Evanthia

“…Purpose To evaluate the pharmacokinetics and efficacy of imatinib in patients with recurrent oligodendroglial tumors. Methods Patients with progressive WHO…”
Get full text

Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of the Combination of Sorafenib and Tanespimycin by VAISHAMPAYAN, Ulka N, BURGER, Angelika M, SAUSVILLE, Edward A, HEILBRUN, Lance K, JING LI, HORIBA, M. Naomi, EGORIN, Merrill J, IVY, Percy, PACEY, Simon, LORUSSO, Patricia M

“…Heat shock protein (Hsp) 90 inhibition affects the Raf kinase signaling pathway and could enhance antitumor effects of sorafenib, a Raf kinase inhibitor. The…”
Get full text

Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08) by Wen, Patrick Y, Yung, W K Alfred, Lamborn, Kathleen R, Norden, Andrew D, Cloughesy, Timothy F, Abrey, Lauren E, Fine, Howard A, Chang, Susan M, Robins, H Ian, Fink, Karen, Deangelis, Lisa M, Mehta, Minesh, Di Tomaso, Emmanuelle, Drappatz, Jan, Kesari, Santosh, Ligon, Keith L, Aldape, Ken, Jain, Rakesh K, Stiles, Charles D, Egorin, Merrill J, Prados, Michael D

“…Platelet-derived growth factor (PDGF) and its receptors (PDGFR) are frequently coexpressed in meningiomas, potentially contributing to their pathogenesis. The…”
Get full text

Limited penetration of anticancer drugs through tumor tissue: A Potential cause of resistance of solid tumors to chemotherapy by TANNOCK, Ian F, LEE, Carol M, TUNGGAL, Jonathon K, COWAN, David S. M, EGORIN, Merrill J

“…Potential causes of drug resistance in solid tumors include genetically determined factors expressed in individual cells and those related to the solid tumor…”
Get full text

Weekly High-Dose Calcitriol and Docetaxel in Metastatic Androgen-Independent Prostate Cancer by BEER, Tomasz M, EILERS, Kristine M, GARZOTTO, Mark, EGORIN, Merrill J, LOWE, Bruce A, HENNER, W. David

“…To determine the safety and efficacy of weekly high-dose oral calcitriol (Rocaltrol, Roche Pharmaceuticals, Basel, Switzerland) and docetaxel (Taxotere,…”
Get full text

Will Imatinib Compromise Reproductive Capacity? by Zamah, Alberuni M., Mauro, Michael J., Druker, Brian J., Oktay, Kutluk, Egorin, Merrill J., Cedars, Marcelle I., Rosen, Mitchell P.

“…Imatinib mesylate is the first in a family of highly effective, minimally toxic, targeted agents used widely to treat Philadelphia‐positive leukemias and…”
Get full text

Phase I Pharmacokinetic-Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin (17AAG, NSC 330507), a Novel Inhibitor of Heat Shock Protein 90, in Patients with Refractory Advanced Cancers by RAMANATHAN, Ramesh K, TRUMP, Donald L, BRUFSKY, Adam M, WONG, Michael K. K, TUTCHKO, Susan, EGORIN, Merrill J, EISEMAN, Julie L, BELANI, Chandra P, AGARWALA, Sanjiv S, ZUHOWSKI, Eleanor G, JING LAN, POTTER, Douglas M, IVY, S. Percy, RAMALINGAM, Sakkaraiappan

“…Purpose: 17-(Allylamino)-17-demethoxygeldanamycin (17AAG), a benzoquinone antibiotic, down-regulates oncoproteins by binding specifically to heat shock protein…”
Get full text